Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Apoptosis signaling" patented technology

Home >> Signaling Pathways >> Apoptosis >> Apoptosis Inducers. Apoptosis, a programmed cell death to eliminate damaged or abnormal cells, is a highly organized physiological process characterized by condensation of nuclear heterochromatin, cell shrinkage and loss of positional organization of organelles in the cytoplasm.

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
Owner:VASCULAR BIOGENICS

B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells

Compositions and methods for restoring killing of cancer cells are provided. Preferably, the compositions are administered to a subject in an effective amount to antagonize, inhibit, reduce, or block B7-H1 mediated signal transduction in cancer cells expressing B7-H1. It has been discovered that B7-H1 transmits an anti-apoptotic signal in cancer cells that increases the resistance of the cancer cells to CTL mediated cytolysis and to Fas induced cell death. It is believed that blocking the transmission of the anti-apoptotic signal by B7-H1 increases the susceptibility of the cancer cells to apoptosis and CTL cytolysis thereby enhancing the death of cancer cells. Preferred compounds or B7-H1 antagonists include antibodies that bind to B7-H1, B7-H1 receptors, or ligands of B7-H1 such as PD-I or B7-1. Additional B7-H1 antagonists include small molecules, for example small molecules that bind the cytoplasmic portion of B7-H1 or the extracellular portion of B7-H1 and inhibit, reduce, block or interfere with B7-H1 signal transduction. Methods for treating one or more symptoms associated with cancer or hyperproliferation are also provided.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Method for knocking out KDM2A gene of HEK293T cells with CRISPR-CAS9 technology

InactiveCN108504657AConducive to research proliferationGood for studying the effects of apoptosisHydrolasesGenetically modified cellsT cellProtein level
The invention provides a method for knocking out a KDM2A gene of HEK293T cells with a CRISPR-CAS9 technology. The method comprises the steps as follows: (1), cell transfection; (2), cell genome extraction; (3), PCR identification; (4), gene level verification; (5), protein level verification: whether K3, K7-1 and K7-2 are KDM2A gene-deficient is further verified by Western blotting after a mutantcell line is verified at the gene level. The invention further provides a KDM2A knockout HEK293T cell line prepared with method and an application of the KDM2A knockout HEK293T cell line as a cell model in study of cell proliferation and apoptosis signaling pathways involved in KDM2A methylase.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES

Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy

InactiveUS20080305088A1Efficiently downregulating angiogenesisBiocidePeptide/protein ingredientsDiseaseSignalling molecules
A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
Owner:VASCULAR BIOGENICS

Apoptosis signal-regulating kinase 1 inhibitors

The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formulawherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Owner:TAKEDA PHARMA CO LTD

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I),and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Rhodamine fluorescent dye containing water-soluble substituent as well as preparation method and application of rhodamine fluorescent dye

The invention discloses a rhodamine dye containing a water-soluble substituent and a functional derivative (a zinc ion probe and an antibody labeled dye) of the rhodamine dye. The rhodamine dye has a structure as shown in a general formula I. After the N-site of a parent nucleus of the dye is connected with different water-soluble substituents, the biocompatibility of the parent nucleus of the dye is greatly improved; and specifically, non-specific staining in cells is remarkably reduced, cell apoptosis signals do not appear any more, phototoxicity is remarkably reduced (the zinc ion probe), labeling efficiency is improved, observation time is prolonged (the antibody labeled dye) and the like. The fluorescent dye disclosed by the invention can be applied to the fields of observing insulin release of in-vitro live pancreas islets, immunofluorescence labeling and the like.
Owner:PEKING UNIV

Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1

The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) . inhibiting compounds of the formulawherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds, to methods and intermediates useful for making the compounds, and to methods of using the compounds.
Owner:TAKEDA PHARMA CO LTD

A hydrogen sulfide donor and its preparation method and use

The invention relates to a donor of hydrogen sulfide and its preparation method and application, belonging to the technical field of medicine. The donor of hydrogen sulfide provided by the present invention has a chemical name of S-(4-fluorobenzyl)-N-(3,4,5-trimethoxybenzoyl)-L-cysteine ​​methyl ester, The chemical structural formula is shown in formula (I); the hydrogen sulfide donor (MTC) provided by the present invention can effectively treat the disease of ischemic stroke by activating the PI3K / AKT pathway, inhibiting the mitochondrial apoptosis signaling pathway, and reducing the internal To achieve the purpose of effective treatment of ischemic stroke, there are various therapeutic targets such as cytoplasmic reticulum stress, activation of ERK-MEK signaling pathway, increase of survival rate of nerve cells or protection of neurons from ischemic injury.
Owner:GUANGZHOU UNIVERSITY

Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

The present invention discloses a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device enables negative selection of mature immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population which is introduced into the device. The device enables an efficient cell selection in simplified and cheaper setting by an off the shelf product—a solution that currently do not exist. The present invention further discloses uses for the device.
Owner:CELLECT BIOTHERAPEUTICS LTD

Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Owner:ENANTA PHARM INC

Apoptosis signal regulating kinase inhibitor and application thereof

ActiveCN111018831ANovel structureIdeal anti-collagen type I synthesis activityOrganic active ingredientsNervous disorderDiseaseReceptor
The invention discloses an apoptosis signal regulating kinase inhibitor and an application thereof. The apoptosis signal regulating kinase inhibitor is a compound represented by general formula I, anda tautomer or a pharmaceutically acceptable salt thereof. The apoptosis signal regulating kinase inhibitor is a compound with a novel structure. Pharmacodynamic experiments prove that the compound has good inhibition capability on an ASK1 receptor, can be used for effectively inhibiting fibrosis in vitro and has low toxicity on normal cells. Therefore, the compound provided by the invention can be used for treating various fibrosis and related diseases.
Owner:CHINA PHARM UNIV

Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof:which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

The present invention discloses compounds of Formula (I),and pharmaceutically acceptable salts thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
Owner:ENANTA PHARM INC

A method for knocking out the kdm2a gene of HEK293T cells using CRISPR-Cas9 technology

InactiveCN108504657BSimple and fast operationThe effect is complete and thoroughHydrolasesGenetically modified cellsT cellProtein level
The invention provides a method for knocking out a KDM2A gene of HEK293T cells with a CRISPR-CAS9 technology. The method comprises the steps as follows: (1), cell transfection; (2), cell genome extraction; (3), PCR identification; (4), gene level verification; (5), protein level verification: whether K3, K7-1 and K7-2 are KDM2A gene-deficient is further verified by Western blotting after a mutantcell line is verified at the gene level. The invention further provides a KDM2A knockout HEK293T cell line prepared with method and an application of the KDM2A knockout HEK293T cell line as a cell model in study of cell proliferation and apoptosis signaling pathways involved in KDM2A methylase.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES

Apoptosis Signal Regulated Kinase Inhibitor and Application

ActiveCN111018831BNovel structureIdeal anti-collagen type I synthesis activityOrganic active ingredientsNervous disorderDiseaseReceptor
The invention discloses a cell apoptosis signal regulating kinase inhibitor and application thereof. Compounds as shown in general formula I, tautomers thereof or pharmaceutically acceptable salts thereof: the present invention provides a class of compounds with novel structures, and pharmacodynamic experiments prove that the compounds of the present invention have a relatively high effect on ASK1 receptors. Good inhibitory ability, can effectively inhibit the formation of fibrosis in vitro, and has low toxicity to normal cells. Accordingly, the compounds of the present invention are useful in the treatment of a variety of fibrosis and related diseases.
Owner:CHINA PHARM UNIV

Devices and methods for selecting apoptosis-signaling resistant cells, and uses thereof

The present invention discloses a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device enables negative selection of mature immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population which is introduced into the device. The device enables an efficient cell selection in simplified and cheaper setting by an off the shelf product—a solution that currently do not exist. The present invention further discloses uses for the device.
Owner:CELLECT BIOTHERAPEUTICS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products